Literature DB >> 12218642

Statins in the prevention and treatment of Alzheimer disease.

Milita Crisby1, Lars A Carlson, Bengt Winblad.   

Abstract

Vascular risk factors such as hypertension and hypercholesterolemia during midlife increase the risk for Alzheimer's disease (AD). Treatment of hypercholesterolemia and other vascular risk factors may have great implications in the prevention of AD. Recent findings illustrate that the sterol metabolism in the brain is an active process, well controlled and regulated by 24-hydroxylase, an enzyme that is uniquely expressed in the brain. The use of statins in ischemic heart disease (IHD) has proven to be a phenomenal advance in pharmacological disease prevention and treatment. A growing body of evidence, suggest that statins exhibit additional benefits that are independent of their cholesterol-lowering actions. Statin treatment has also considerable effect in prevention of ischemic stroke. In animal models of ischemic stroke, statins have proven to reduce infarct size through up-regulation of endothelial nitric oxide synthases. Data from recent observational studies have revealed a potential role for statins in prevention of AD. The following review comments the processes leading to dementia including the involvement of cholesterol regulation, cerebral circulation and inflammation in development of dementia. The mechanisms by which statins may be beneficial in controlling these processes is discussed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12218642     DOI: 10.1097/00002093-200207000-00001

Source DB:  PubMed          Journal:  Alzheimer Dis Assoc Disord        ISSN: 0893-0341            Impact factor:   2.703


  12 in total

1.  Lipid lowering agents are associated with a slower cognitive decline in Alzheimer's disease.

Authors:  I Masse; R Bordet; D Deplanque; A Al Khedr; F Richard; C Libersa; F Pasquier
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-12       Impact factor: 10.154

2.  Commentary on "the Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics".

Authors:  Marwan N Sabbagh
Journal:  Alzheimers Dement       Date:  2008-04-21       Impact factor: 21.566

3.  Memory deficits and neurochemical changes induced by C-reactive protein in rats: implication in Alzheimer's disease.

Authors:  Huan-Bing Lin; Xue-Mei Yang; Tie-Jun Li; Yu-Fang Cheng; Han-Ting Zhang; Jiang-Ping Xu
Journal:  Psychopharmacology (Berl)       Date:  2009-03-05       Impact factor: 4.530

4.  Use of statins and risk of hospitalization with dementia: a Danish population-based case-control study.

Authors:  Henriette Thisted Horsdal; Anne Vingård Olesen; Christiane Gasse; Henrik Toft Sørensen; Robert C Green; Søren Paaske Johnsen
Journal:  Alzheimer Dis Assoc Disord       Date:  2009 Jan-Mar       Impact factor: 2.703

Review 5.  Dietary lipids in the aetiology of Alzheimer's disease: implications for therapy.

Authors:  Janelle L Cooper
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

6.  Effects of statins on cognitive function in patients with Alzheimer's disease in galantamine clinical trials.

Authors:  Bengt Winblad; Vesna Jelic; Paul Kershaw; Joan Amatniek
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

7.  Once-daily transdermal rivastigmine in the treatment of Alzheimer's disease.

Authors:  Andreas Wentrup; Wolfgang H Oertel; Richard Dodel
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

8.  Lipid-lowering effects of ethyl 2-phenacyl-3-aryl-1H-pyrrole- 4-carboxylates in rodents.

Authors:  Justin M Holub; Kathy O'Toole-Colin; Adam Getzel; Anthony Argenti; Michael A Evans; Daniel C Smith; Gerard A Dalglish; Shahzad Rifat; Donna L Wilson; Brett M Taylor; Ulander Miott; Josephine Glersaye; Kam Suet Lam; Bryan J McCranor; Joshua D Berkowitz; Robert B Miller; John R Lukens; Keith Krumpe; John T Gupton; Bruce S Burnham
Journal:  Molecules       Date:  2004-02-28       Impact factor: 4.411

9.  Variability in the diagnosis and management of patients with Alzheimer's disease and cerebrovascular disease: results from the GALATEA multicentre, observational study.

Authors:  Pedro Gil; José Luis Dobato Ayuso; José Manuel Marey; Manuel Antón; Carlos Guzmán Quilo
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

Review 10.  Treating vascular risk factors and maintaining vascular health: is this the way towards successful cognitive ageing and preventing cognitive decline?

Authors:  K Alagiakrishnan; P McCracken; H Feldman
Journal:  Postgrad Med J       Date:  2006-02       Impact factor: 2.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.